226 related articles for article (PubMed ID: 34884931)
1. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
Boi D; Souvalidou F; Capelli D; Polverino F; Marini G; Montanari R; Pochetti G; Tramonti A; Contestabile R; Trisciuoglio D; Carpinelli P; Ascanelli C; Lindon C; De Leo A; Saviano M; Di Santo R; Costi R; Guarguaglini G; Paiardini A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884931
[TBL] [Abstract][Full Text] [Related]
2. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
[TBL] [Abstract][Full Text] [Related]
3. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
[TBL] [Abstract][Full Text] [Related]
4. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M
Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.
Richards MW; Burgess SG; Poon E; Carstensen A; Eilers M; Chesler L; Bayliss R
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13726-13731. PubMed ID: 27837025
[TBL] [Abstract][Full Text] [Related]
7. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
8. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
[TBL] [Abstract][Full Text] [Related]
9. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
[No Abstract] [Full Text] [Related]
10. Aurora kinase A is a possible target of OSU‑03012 to destabilize MYC family proteins.
Silva A; Wang J; Lomahan S; Tran TA; Grenlin L; Suganami A; Tamura Y; Ikegaki N
Oncol Rep; 2014 Sep; 32(3):901-5. PubMed ID: 25017515
[TBL] [Abstract][Full Text] [Related]
11. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
12. A moving target: structure and disorder in pursuit of Myc inhibitors.
Bayliss R; Burgess SG; Leen E; Richards MW
Biochem Soc Trans; 2017 Jun; 45(3):709-717. PubMed ID: 28620032
[TBL] [Abstract][Full Text] [Related]
13. Drugging MYCN through an allosteric transition in Aurora kinase A.
Gustafson WC; Meyerowitz JG; Nekritz EA; Chen J; Benes C; Charron E; Simonds EF; Seeger R; Matthay KK; Hertz NT; Eilers M; Shokat KM; Weiss WA
Cancer Cell; 2014 Sep; 26(3):414-427. PubMed ID: 25175806
[TBL] [Abstract][Full Text] [Related]
14. Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.
Rishfi M; Krols S; Martens F; Bekaert SL; Sanders E; Eggermont A; De Vloed F; Goulding JR; Risseeuw M; Molenaar J; De Wilde B; Van Calenbergh S; Durinck K
Eur J Med Chem; 2023 Feb; 247():115033. PubMed ID: 36549117
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological activity of N
Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
17. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
18. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia.
Katsha A; Soutto M; Sehdev V; Peng D; Washington MK; Piazuelo MB; Tantawy MN; Manning HC; Lu P; Shyr Y; Ecsedy J; Belkhiri A; El-Rifai W
Gastroenterology; 2013 Dec; 145(6):1312-22.e1-8. PubMed ID: 23993973
[TBL] [Abstract][Full Text] [Related]
19. Aurora kinases as targets in drug-resistant neuroblastoma cells.
Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
[TBL] [Abstract][Full Text] [Related]
20. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
